anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Table

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 60,557
Current window 33,541-33,570
Pages 2,019
Rows per page 30
Component: Tableclear collectionreset all
18 30 60

Component

33,541-33,570 of 60,557

filter-aware
21
The table reconciles GAAP operating cash flow to a non-GAAP adjusted figure by adding/subtracting specific items like legal settlements, separation costs, and Amoun operating activities.Bausch Health Companies | Investor Conference Presentation Deck | 25 slides · Bausch Health
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
22
The table provides a detailed breakdown of adjustments including impairments, restructuring, and litigation costs.Bausch Health Companies | Investor Conference Presentation Deck | 25 slides · Bausch Health
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
07
The table includes both reported and organic growth metrics, with footnotes detailing non-GAAP adjustments and segment realignments.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
Includes both GAAP and non-GAAP financial measures with variance analysis.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
09
Includes a callout box highlighting specific GAAP and non-GAAP cash flow figures.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
10
Includes footnotes detailing specific debt adjustments and divestiture impacts.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
11
The slide uses a blue box to visually emphasize the 2021-2024 period with zero debt maturities.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
36
The slide details the financial impact of segment realignments, showing reported vs. restated figures.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
39
The table tracks financial performance changes for specific product lines following patent expirations.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
40
LOE = Loss of Exclusivity. Data shows significant revenue and profit declines across all business units.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
41
LOE stands for Loss of Exclusivity. The table tracks financial variance between two forecast periods.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
42
The table compares inventory levels across two years, highlighting the change in months on hand for each business unit.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
43
The table highlights inventory levels for specific business units, showing an increase in months on hand across all units in the 2021 period compared to 2020.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
44
Includes non-GAAP metrics and segment-specific performance data.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
45
The slide highlights a 6% organic revenue growth for the Salix segment.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
46
The slide highlights a 1% organic revenue decline for the segment.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
47
Includes segment-specific revenue and operating expense breakdown.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
48
The slide includes a specific callout for the revenue decline of the WELLBUTRIN/APLENZIN product line.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
49
Includes detailed footnotes regarding non-GAAP adjustments and constant currency calculations.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
50
Includes non-GAAP metrics and segment-specific growth rates.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
51
Includes non-GAAP metrics like EBITA and organic growth.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
52
Includes non-GAAP metrics like EBITA and organic growth.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
53
Includes non-GAAP metrics like EBITA and organic growth.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
54
The slide highlights a 7% decline in combined WELLBUTRIN/APLENZIN revenue.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
55
Includes footnotes regarding non-GAAP information and constant currency calculations.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
56
Includes footnotes regarding non-GAAP information and constant currency calculations.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
57
The table tracks revenue in millions of dollars for 10 products across 5 quarters (3Q20 to 3Q21).Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
58
The table tracks revenue in millions for 10 product lines across 5 quarters (3Q20 to 3Q21).Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
59
The table lists 10 products with their respective quarterly revenues in millions of dollars.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit
60
Data represents international sales only.Bausch Health Companies | Results Presentation Deck | 91 slides · Bausch Health
Conference presentation Investor relations Beat · Action1 hit